ArticleAntimicrobial agents and chemotherapy2014
Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2024Trial
- Hospital length of stay and cost associated with routine-care documentation of probable or suspected fungal infection among patients hospitalized with acute myeloid leukemia: a propensity score analysis.BMC infectious diseases · 2026Article
- Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.Infection · 2026Article
- Breakthrough Invasive Mold Infections in Hematologic Cases: Relevance of the Host's Factors.Open forum infectious diseases · 2025Article
- Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.Journal of cancer research and clinical oncology · 2023Article
- Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2022Article
- T-lymphocytes Expression of Toll-like Receptors 2 and 4 in Acute Myeloid Leukemia Patients with Invasive Fungal Infections.Mediterranean journal of hematology and infectious diseases · 2022Article
- Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Article
- A Prospective Observational Multi-institutional Study on Invasive Fungal Infections Following Chemotherapy for Acute Myeloid Leukemia (MISFIC Study): A Real World Scenario from India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Article
- Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy.Open forum infectious diseases · 2019Article
- The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2018Article
- Invasive fungal infections in high-risk patients: report from TIMM-8 2017.Future science OA · 2018Article
- Review
- Primary fungal prophylaxis in acute leukemia patients with different risk factors: retrospective analysis from the CAESAR study.International journal of hematology · 2017Article
- Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen.Frontiers in microbiology · 2016Review
- Acute myeloid leukaemia: challenges and real world data from India.British journal of haematology · 2015Article
- Observational
- The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis.ClinicoEconomics and outcomes research : CEOR · 2015Article
- Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?".Antimicrobial agents and chemotherapy · 2014Article
- Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although primary antifungal prophylaxis (PAP) is routinely administered in patients with acute myeloid leukemia (AML) during remission-induction and consolidation chemotherapy, the impact of PAP on the incidence of invasive fungal infections (IFIs) is not well described. We retrospectively analyzed the incidence of IFIs in 152 patients with AML who had been admitted to a tertiary cancer center between August 2009 and March 2011 and received PAP within 120 days after first remission-induction chemotherapy. We excluded patients who had undergone stem cell transplantation. Patients received a PAP drug with anti-Aspergillus activity during 72% (7,660/10,572) of prophylaxis-days. The incidence of documented IFIs (definite or probable according to revised European Organization for Research and Treatment of Cancer [EORTC] criteria) was 2.0/1,000 prophylaxis-days (95% confidence interval [CI], 1.23 to 3.04). IFIs due to molds were more common than IFIs due to yeasts (1.5/1,000 prophylaxis-days versus 0.4/1,000 prophylaxis-days; P = 0.01). Echinocandin-based PAP (8.6 and 7.1/1,000 prophylaxis-days, respectively) was associated with higher rates of documented IFIs than anti-Aspergillus azoles (voriconazole or posaconazole) (2.4 and 1.1/1,000 prophylaxis-days, respectively) at both 42 days (P = 0.03) and 120 days (P < 0.0001) after first remission-induction chemotherapy. The incidence of overall (documented and presumed) IFIs (P < 0.001), documented IFIs (P < 0.01), and empirical antifungal therapies (P < 0.0001) was higher during the first 42 days than after day 42. Despite the broad use of PAP with anti-Aspergillus activity, IFIs, especially molds, remain a significant cause of morbidity and mortality in AML patients, predominantly during the remission-induction phase. Patients receiving echinocandin-based PAP experienced higher rates of IFIs than did those receiving anti-Aspergillus azoles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.